Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 27, Issue 4, 2008, Pages 511-513

  Alexiou, Ioannis ^b   Germenis, Anastasios ^a   Koutroumpas, Athanasios ^b   Kontogianni, Anastasia ^b   Theodoridou, Katerina ^a   Sakkas, Lazaros I ^b  

^a University of Thessaly School of Medicine   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Anti cyclic citrullinated antibodies; Autoantibodies; Biomarkers; Extra articular manifestations; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; PREDNISONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPISCLERITIS; FELTY SYNDROME; GREECE; HUMAN; INFLAMMATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; NEUROPATHY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SCLERITIS; SJOEGREN SYNDROME; VASCULITIS;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FELTY'S SYNDROME; GREECE; HUMANS; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; PULMONARY FIBROSIS; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; RHEUMATOID NODULE; SEROSITIS; SJOGREN'S SYNDROME; VASCULITIS;

EID: 40949102336     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0800-1     Document Type: Article

References (17)

1. Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis. A population-based analysis of trends over 40 years. Arthritis Rheum 48:54-8
2. Ronnelid J, Wick MC, Lampa J et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CCP) during 5 year follow up in early rheumatoid arthritis: Anti-CCP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744-49
3. Turesson C, Jacobsson LTH, Sturfelt G et al (2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66:59-64
4. van Gaalen FA, van Aken J, Huizinga TWJ et al (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. Arthritis Rheum 50:2113-21
5. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC et al (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor to develop rheumatoid arthritis. Arthritis Rheum 54:1117-21
6. Boki KA, Panayi GS, Vaughan RW et al (1992) HLA-class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared epitope accounts for the disease in only a minority of Greeks. Arthritis Rheum 35:749-55
7. Alexiou I, Germenis A, Ziogas A et al (2007) Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 8:37-43
8. Zendman AJW, van Venrooij WJ, Pruijn GJM (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 45:20-25
9. Nishimura K, Sugiyama D, Kogata Y et al (2007) Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid a factor for rheumatoid arthritis. Ann Intern Med 146:816-7
10. De Rycke L, Peene I, Hoffman IEA et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587-93
11. Korkmaz C, Us T, Kasifoglu T, Akgun Y (2006) Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem 39:961-5
12. Klareskog L, Stolt P, Lundendberg K et al (2006) A new model for the etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reaction to autoantigens modified by citrullination. Arthritis Rheum 54:38-46
13. Pedersen M, Jacobsen S, Garred P et al (2007) Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis. A nationwide case-control study in Denmark. Arthritis Rheum 56:1446-53
14. Stavropoulos C, Spyropoulou M, Koumantaki Y et al (1997) HLA-DRB1* genotypes in Greek rheumatoid arthritis patients: Association with disease characteristics, sex and age at onset. Br J Rheumatol 36:141-2
15. Voskuyl AE, Zwinderman AH, Westedt ML et al (1996) Factors associated with the development of vasculitis in rheumatoid arthritis: Results of a case-control study. Ann Rheum Dis 55:190-2
16. Alessandri C, Bombardieri M, Papa N et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218-21
17. Caramaschi P, Biasi D, Tonolli E et al (2005) Antibodies against cyclic citrullinated peptides in patients with rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58-62